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A total of 46 ciprofloxacin-resistant (CipR) Streptococcus pneumoniae strains were isolated 
from 1991 to 2001 at Hospital of Bellvitge. Five of these strains showed unexpected high 
nucleotide variations in the quinolone-resistance-determining region (QRDR) of their parC, 
parE and gyrA genes. The nucleotide sequence of the full-length parC, parE, and gyrA genes 
of one of these isolates revealed a mosaic structure compatible with interspecific 
recombination origin. Southern blot analysis and nucleotide sequence determinations 
showed the presence of an ant-like gene in the intergenic parE-parC region of the S. 
pneumoniae CipR isolates with high variations in their parE and parC QRDRs. The ant-like 
gene was absent in typical S. pneumoniae strains, whereas it was present in the intergenic 
parE-parC region of the viridans group streptococci (Streptococcus mitis and Streptococcus 
oralis). These results suggest that the viridans group streptococci are acting as donors in the 
horizontal transfer of fluoroquinolone-resistant genes to S. pneumoniae.  
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Streptococcus pneumoniae (the pneumococcus) remains the leading bacterial cause of 
community-acquired pneumonia, meningitis and otitis media. The emergence and spreading of 
resistance to penicillin and macrolide antibiotics (17, 25, 41), has made the selection of optimal 
antimicrobial therapy difficult. A parallel increasing resistance to those antibiotics has also been 
observed for the viridans group streptococci (VS) (1, 2, 7, 8), which are commensals of the 
oropharyngeal tract of healthy individuals, but also a major cause of endocarditis (46) and 
bacteremia in neutropenic patients (3, 7, 8, 15). Fluoroquinolones with increased activity against 
S. pneumoniae, such as levofloxacin, moxifloxacin and gatifloxacin are now being recommended 
for the treatment of patients with community-acquired pneumonia (5). Although the prevalence of 
ciprofloxacin resistance in S. pneumoniae is still low in Spain (3- 7%)(32, 43) and Canada (2%) 
(9), higher values have been found for the VS. Among 1,046 VS characterized as S. mitis isolated 
during 1993-2001 at Hospital of Bellvitge the prevalence of ciprofloxacin resistance was of 16.6 
% (unpublished data), a figure very similar to the 11.4% reported in Canada (11). An increase in 
resistance to fluoroquinolones in both S. pneumoniae and VS would be expected as a 
consequence of a widespread use of these compounds. Prior fluoroquinolone administration is an 
important risk factor for resistant strain selection, as observed for respiratory tract infections 
caused by ciprofloxacin resistant (CipR) (44) and levofloxacin-resistant (10, 54) S. pneumoniae. 
Likewise, emergence of CipR VS blood isolates from neutropenic cancer patients that received 
fluoroquinolone prophylaxis has been reported (23, 55).  
Bacterial resistance to fluoroquinolones occurs mainly by alteration of drug targets. The 
intracellular fluoroquinolone targets are DNA topoisomerase IV (topo IV) and DNA gyrase 
(gyrase), enzymes that function by passing a DNA double helix through another, using a transient 
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double-strand break (14). DNA gyrase, an A2B2 complex, encoded by gyrA and gyrB, catalyses 
ATP-dependent negative supercoiling of DNA to relieve the topological stress generated during 
DNA replication and transcription. Topoisomerase IV, a C2E2 complex encoded by parC and 
parE, is essential in chromosome partitioning. The amino acid sequences of ParC and ParE are 
homologous to those of GyrA and GyrB, respectively (29).  
Genetic and biochemical studies have shown that topo IV is the primary target for 
ciprofloxacin and that gyrase is a secondary target in S. pneumoniae (20, 28, 42, 52). Resistance 
mutations have been identified in a discrete region of ParC, ParE and GyrA termed the quinolone 
resistance-determining region (QRDR). The VS share the same mechanism of ciprofloxacin 
resistance (23), and it has been possible to transform S. pneumoniae cells to ciprofloxacin 
resistance with DNA from CipR VS in the laboratory (23, 27). The VS could be as a reservoir of 
fluoroquinolone resistance by acting as DNA donors in the horizontal transfer to pneumococci, 
similarly to that observed for penicillin resistance (50). The high level of intra-species sequence 
variation in the DNA topoisomerase genes of VS (6, 23) and the mosaic structures of parC and 
gyrA in S. pneumoniae clinical isolates (6, 22, 57), led us to suggest that genetic interchange of 
the fluoroquinolone target genes occurs both into VS and between VS and pneumococci. In this 
work we present evidence supporting the hypothesis of VS being the donors in the recombination 
events yielding DNA topoisomerase mosaic genes in S. pneumoniae CipR clinical isolates. 
 
MATERIALS AND METHODS 
 Bacterial strains, serotyping and susceptibility tests. The strains used in this work were 
isolated from sputum of adult patients. Only one isolate per patient was evaluated. Identification 
was according to standard methodology using the following tests: colonial morphology, Gram´s 
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stain, catalase reaction, optochin susceptibility and bile solubility. The strains were serotyped by 
detection of quellung reaction using antisera provided by the Staten Seruminstitut (Copenhagen) at 
the Spanish Pneumococcus Reference Laboratory (Centro Nacional de Microbiología, Instituto de 
Salud Carlos III, Majadahonda Madrid). Identification of VS was by standard methods (16, 48). 
MICs were determined by the microdilution method, using cation-adjusted Mueller-Hinton broth 
supplemented with 2.5% lysed horse blood as recommended by the National Committee for 
Clinical Laboratory Standards (NCCLS) (40). The inoculum was prepared by suspension of several 
colonies from an overnight blood agar culture in Mueller-Hinton broth and adjusting the turbidity to 
the 0.5 McFarland standard (ca. 108 CFU/ml). The suspension was further diluted to provide a final 
bacterial concentration of 104 CFU/ml in each well of the microdilution trays. Plates were covered 
with plastic tapes and incubated in ambient atmosphere at 37ºC for 20-24 h. MIC was defined as the 
lowest concentration of drug that inhibited visible growth. S. pneumoniae ATCC 49619 and  S. 
pneumoniae  R6 strains were used for the quality control. Ciprofloxacin was kindly provided by 
Bayer.  
 Southern blot analysis. For identification of S. pneumoniae strains, plasmid pCE3 (18), 
containing a 0.65-kb fragment coding for the N-terminus of the major pneumococcal autolysin 
(amidase) was used as a source of the lytA DNA probe. Plasmid pJCP191 (51), containing a 1.6-
kb fragment coding for the complete pneumococcal pneumolysin gene was used as a source of 
pnl DNA probe and was kindly provided by S. Taira. The parC and parE probes were obtained 
by PCR amplification of the R6 laboratory strain with oligonucleotides parCUP; parCDOWN; 
parEUP; and parEDOWN (Table 1). The ant probe was obtained by amplification of strain 3870 
DNA with oligonucleotides antUP and antDOWN (Table 1). Al probes were labeled with the 
Phototope-Star Detection Kit (New England Biolabs). Southern blot and hybridization followed 
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the manufacturer’s instructions. 
 PCR amplification and DNA sequence determination. S. pneumoniae chromosomal DNA 
was obtained as described previously (19). DNA topoisomerase QRDRs were amplified from 
genomic DNA by the polymerase chain reaction (PCR) as described (23, 38). The parE, parC and 
gyrA genes were amplified with the following primers, based on published sequences (4, 19, 21, 
38): parEUP and parEDOWN; parCUP and parCDOWN; gyrAUP1, and gyrADOWN (Table 1). 
PCR amplifications were performed using 0.5 units of Thermus thermophilus thermostable DNA 
polymerase (Biotools), 1 g of chromosomal DNA, 0.4 M (each) of the synthetic 
oligonucleotide primers, 0.2 mM of each dNTP, and 2 mM MgCl2 in a final volume of 50 l. To 
amplify the atpC and atpA genes, oligonucleotides atpWO and atpB56, were used (Table 1). 
Amplification was achieved with an initial cycle of 1 min denaturation at 94ºC, and 30 cycles of 
30 seconds at 94ºC, 90 seconds at 55ºC and 80 seconds polymerase extension step at 72ºC, with a 
final 8 min 72ºC extension step and slow cooling at 4ºC. Gel electrophoresis of PCR products 
was carried out in agarose gels as described (49). DNA fragments were purified using 
MicroSpinTM S400 HR columns (Amersham Pharmacia Biotech) and sequenced on both strands 
with an Applied Biosystems Prism 377 DNA sequencer, accordingly to protocols provided by the 
manufacturer with both the primers used for the PCR amplifications and internal primers. 
 DNA sequence determination and phylogenetic analysis. DNA sequencing was carried out 
with an Applied Biosystems Prism 377 DNA sequencer. Sequencing reactions were performed 
accordingly to protocols provided by Applied Biosystems with the primers used for the PCR 
amplifications and with internal primers. Phylogenetic analysis was performed by using the 
MEGA 2.1 programs (31), available at http://www.megasoftware.net. Dendograms were 
constructed by the UPGMA (Unweighted Pair Group Method with Arithmetic Mean) method 
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with the Kimura-2 parameter. The percentage bootstrap confidence levels of internal branches, as 
defined by MEGA (31), were calculated from 1000 random resamplings. 
 Nucleotide sequence accession numbers. The new DNA sequences reported in this paper 
have been assigned the following GenBank Accession numbers: AY166963, AY166965, 
AY167641 to AY167643, AY168409 to AY168412, AY184477 (ant regions), AY167637 and 
AY167640 (atpCA regions), AY157690 (parC of S. pneumoniae 4391), AY157689 (gyrA of S. 
pneumoniae 4391), AY157687, AY157688 and AY167691 (parE sequences). The atpCA region 
of S. pneumoniae 4589 is identical to that of S. pneumoniae 3180 (accession number: AF171000). 
 
RESULTS  
Characterization of S. pneumoniae isolates. An epidemiological study performed at 
Hospital of Bellvitge during an 11-year period (1991-2001) revealed 2.3 % (89 out of 3819) CipR 
(MICs  4 g/ml) S. pneumoniae isolates (unpublished results). The parC, parE, gyrA, and gyrB 
QRDRs of a total of 46 CipR strains were characterized. All strains showed low variations (1%) 
in the nucleotide sequence of gyrB QRDR. However, although 41 of the 46 strains showed 
variations 1% in their parE, parC and gyrA QRDRs, 5 strains (numbers 3180, 3870, 4391, 4589, 
and 5237) exhibited unexpected high nucleotide variations (> 4%) in at least one of these 
sequences. Since high nucleotide sequence variations in the QRDRs have been associated with a 
mosaic structure in the parC and gyrA genes of strains 3180 and 3870 (21), we hypothesized that 
a gene showing QRDR nucleotide sequence variation higher than 4% will have a mosaic structure 
indicative of DNA interspecific horizontal transfer. Comparison of the parC, parE and gyrA 
QRDRs of these five mosaic strains with that of S. pneumoniae R6, the CipR S. pneumoniae 4638 
typical isolate (not showing variations in their QRDRs), S. mitis and S. oralis type strains and 
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three CipR S. mitis isolates was performed (Fig. 1, Table 2 ). Mosaic strains showed nucleotide 
sequence variations higher than 4% for parE  (5 out of 5 strains), parC (5 out of 5 strains) and 
gyrA (4 out of 5 strains, exception being strain 5237) when compared with S. pneumoniae R6 and 
S. pneumoniae 4638. All CipR S. pneumoniae and VS strains showed typical mutations yielding 
changes in ParC S79 (to F, N, or Y) and GyrA S81 (to F or Y) (Fig. 1, Table 2 ). Two additional 
amino acid changes (ParC K137N and ParE I460V ), not involved in resistance, which are present 
 both in CipS and CipR S. pneumoniae strains and that are consequently considered as 
polymorphisms, were found in S. pneumoniae 4638. All five S. pneumoniae strains showing high 
parC QRDR nucleotide sequence variations showed the same amino acid change (N91D) that is 
present in ParC of both CipS and CipR VS strains. When the GyrA QRDR was considered, the 
S114G amino acid change was observed in the four S. pneumoniae strains showing high 
nucleotide sequence variations in their gyrA QRDR and in both CipS and CipR VS strains. The 
presence of ParC N91D and GyrA S114G in VS strains and in CipR S. pneumoniae mosaic strains 
suggests that mosaic strains have been originated by recombination with VS. Additional amino 
acid changes were observed in S. pneumoniae 5237 (ParC I126V and E135D changes), S. mitis 
181731-3 (GyrA M90G) and S. mitis 181732-2 (GyrA N150S change; ParE P424A, I460L, 
A463E, K466N and A468S changes). These changes are an indication of the high level of intra-
species variation in the VS. 
Identification of the strains as S. pneumoniae by using molecular tools. We have previously 
characterized S. pneumoniae 3180 and S. pneumoniae 3870 (21) by hybridization with pnl and 
lytA pneumococcal specific probes (18, 24, 45, 47, 56). In the present study identical tests were 
performed with the rest of the mosaic strains. Hybridization with the pnl probe detected single 
fragments of about 5-kb in S. pneumoniae strains ClaI-digested DNA, while no hybridization was 
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observed with the VS DNAs. All S. pneumoniae strains showed, as expected, hybridization with 
the lytA probe in a 1.2-kb Hind III chromosomal fragment, while the VS strains did not. 
Sequencing of a region spanning 960 nucleotides including atpC and atpA genes that are 
responsible for the unique optochin susceptibility of the pneumococcus (19, 33, 39) allowed 
further characterization of the strains. All S. pneumoniae strains showed high homogeneity (less 
than 0.7% nucleotide sequence variation), while variations among S. pneumoniae R6 and VS type 
strains was higher than 20%. These values are in agreement with the comparisons of the 
amylomaltase gene sequences:  0.5% S. pneumoniae intraspecies variation (13), and 4-6% 
divergence between S. pneumoniae and S. oralis (12). A phylogenetic tree was constructed with 
the concatenated atpC and atpA genes of S. pneumoniae and VS strains and of Bacillus 
halodurans as outgroup (Fig. 2).The S. pneumoniae strains formed a monophyletic group within 
the tree. 
 Analysis of the sequences of the parC, parE and gyrA genes. To asses the 
recombinational origin of the mosaic strains, the parE sequence of S. pneumoniae 4391 and VS 
type strains was determined. Oligonucleotides based on the S. pneumoniae R6 sequence were 
used to obtain and sequence PCR products. Nucleotide sequence variations between 8 and 12% 
were observed among the strains (Fig. 3). Similar variations were observed between the parE 
sequence of strain 4391 and that of S. pneumoniae R6 or S. pneumoniae TIGR4. However, the 
parE sequences of R6 and TIGR4 were almost identical (1% variation). The variations found 
could be organized in blocks with different degrees of relatedness. The limits of the blocks were 
determined by inspection, with the only limitation being at least a 4% difference in divergence 
between two contiguous blocks. Two blocks were detected in S. pneumoniae 4391 while no 
blocks were detected in VS type strains (Fig. 3). A WU-blast search with S. pneumoniae 4391 
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ParE on the Swiss-Prot sequence database was performed to select sequences to be used in the 
construction of the tree  shown on Fig. 2. Only the nucleotide sequences of the more similar 
proteins, which corresponded to ParE subunits of S. pneumoniae TIGR4 and R6 strains, along 
with the sequences determined in this work and that of B. halodurans as an outgroup, were used. 
The parE sequences of S. pneumoniae 4391, S. mitis 12261, S. pneumoniae R6 and S. 
pneumoniae TIGR4 formed a statistically significant group within the tree. 
 The full-length sequences of parC and gyrA of strain 4391 were also determined. These 
sequences showed variations of 8.9% for gyrA and 5.8% for parC when compared to the S. 
pneumoniae R6 sequence that could be organized in blocks of divergence (Fig. 3).  
 Characterization of the parE-parC intergenic regions. Several PCR amplifications were 
performed to determine the sequences of parE and parC genes of S. pneumoniae 4391. When 
oligonucleotides parEdownR (coding for the last 4 ParE residues) and parC26R 
(complementaryto the strand coding for ParC residues 26 to 33) were used, a product of about 6 
kb was obtained. Since the intergenic parE-parC region of S. pneumoniae R6 is 420-bp long (38), 
these results suggested a different genetic organization of the parE-parC chromosomal region in 
strain 4391. To know if this was the case for the rest of the CipR S. pneumoniae mosaic strains, 
the length of their parE-parC intergenic regions was determined and compared with that of S. 
pneumoniae R6, the typical CipR S. pneumoniae 4638 strain and both CipS and CipR VS strains. 
PCR amplifications with four pairs of oligonucleotides located upstream parE, and in the parC 
N-terminus (parEUP and parC26R), upstream of parE and downstream parC (parEUP and 
parCDOWN), downstream parE and in the parC N-terminus (parEDOWNR and parC26R), and 
downstream of parE and downstream parC (parERDOWNR and ParCDOWN) were performed. 
The size of these PCR products were compatible with intergenic regions for R6 and 4638 of 0.4 
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kb, for VS strains in the range of 1 to 2.5 kb, and for the S. pneumoniae CipR mosaic strains in the 
2 to 6.2 kb-range. Southern blot experiments using parC and parE specific probes and digestions 
of PCR products were performed (not shown) to construct physical maps for EcoRV and NcoI of 
the parE-parC regions (Fig. 4). These experiments showed that, except for S. pneumoniae R6 and 
S. pneumoniae 4638, the estimated sizes on the intergenic parE-parC regions were in the 1- to-
6.2 kb range. Among S. pneumoniae mosaic strains, 3870 and 4589 share the same physical maps 
of the parE-parC chromosomal region (Fig. 4). Among VS strains, the same parE-parC physical 
map was observed for S. mitisT 12261 and S. mitis 181731-3. 
  Characterization of the ant gene. The nucleotide sequences of the parE-parC intergenic 
region of S. oralisT 10557, S. pneumoniae 3870 and S. pneumoniae 4589 revealed the presence of 
an open reading frame, ant, recently described in the intergenic parE-parC region of the S. mitis 
isolate CIP 103335T (27). To check if this gene was also present in other parE-parC intergenic 
regions, a probe for ant of S. pneumoniae 3870 was constructed by PCR with oligonucleotides 
antUP and antDOWN. This probe was used to hybridize the Southern blots of DNA cut with 
EcoRV and NcoI described above. These experiments (Fig. 5) confirmed the presence of ant in 
the intergenic parE-parC region of all VS strains checked and in all S. pneumoniae strains with a 
suspected recombinational origin. However, not hybridization was observed with several S. 
pneumoniae strains, including R6 and ATCC strains 49619, 700669 and 700671, the two latter 
being representative of Spain23F-1 and Spain9V-3 clones, respectively (35). In addition, two low-
level CipR (strains 3724, 4837) and two high-level CipR (strains 4638 and 4235) pneumococcal 
clinical isolates with typical ParC, ParE, and GyrA QRDRs (data not shown) did not show 
hybridization with the ant probe (Fig. 5). These results show that the presence of ant is a 
characteristic of VS and that is present in the parE-parC intergenic region of S. pneumoniae 
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mosaic strains. The ant open reading frame is homologous to ant genes encoding aminoglycoside 
adenylyltransferase enzymes from bacteria (36) but was not associated with any particular 
phenotype in the S. pneumoniae mosaic strains or in VS strains (data not shown). Comparisons of 
the ant nucleotide sequence of S. pneumoniae mosaic strains and VS strains showed similarities 
between 99.7% and 65% (Fig. 2) and identity among S. pneumoniae mosaic strains 4589 and 
3870. The ant sequences determined in this work were analyzed along with S. mitis CIP and B. 
halodurans and used in the construction of a phylogenetic tree shown on Fig.2.The S. 
pneumoniae mosaic strains and VS strains formed a separate group within the tree, being S. oralis 
10557 the only exception. 
DISCUSSION 
 The QRDRs of the DNA topoisomerase genes of 46 CipR S. pneumoniae strains isolated during 
an 11-year period at Hospital of Bellvitge were characterized. Four isolates showed high nucleotide 
variations (>4%) in three genes (parC, parE and gyrA) and one isolate in two (parE and parC) (Fig. 
1). We hypothesized that this unexpected QRDR variations were reflect of the variations present in 
the whole gene. An isolate with a nucleotide variation higher than 4% in the QRDR on a specific 
gene with respect to S. pneumoniae R6, will likely have a mosaic structure originated by 
recombination. This hypothesis was confirmed for all those genes that we have fully sequenced, 
such as parC of strains 3180, 3870 (21) and 4391 (Fig. 3), parE of strain 4391 (Fig. 3), and gyrA of 
strains 3180, 3870 (21) and 4391 (Fig. 3). Other authors have reported results compatible with that 
hypothesis (6, 57). Among the five mosaic strains, four would have a mosaic structure in their 
parC, parE, and gyrA genes and one strain in their parC and parE genes. The genetic organization 
of the parE-parC chromosomal region of the five S. pneumoniae mosaic strains isolated was 
different from that of typical S. pneumoniae strains, such as R6 and 4638. The size of the intergenic 
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parE- parC region in the mosaic strains and VS was longer than in typical S. pneumoniae strains 
(Fig. 4). While the sizes of the intergenic regions in VS strains varied between 1 and 2.5 kb, those 
from the S. pneumoniae mosaic strains studied in this work varied between 1.9 and 6.2 kb (Fig. 4). 
These figures are compatible with an interchange of genetic material between VS and pneumococci. 
Supporting this hypothesis, the ant gene is present in the intergenic parE- parC region, both in S. 
pneumoniae mosaic strains and in VS, but is absent in typical S. pneumoniae strains (Fig 5). In 
addition, the ant gene was not found in the S. pneumoniae R6 (26) or the S. pneumoniae TIGR4 
(53) sequence databases. Although the nucleotide sequence of ant genes showed high heterogeneity, 
comparison of this gene from VS and S. pneumoniae mosaic strains with those present in the data 
bases showed that ant genes from S. pneumoniae mosaic strains and VS formed a separate group 
within the phylogenetic tree (Fig. 2 ). Similar results were obtained when the parE genes were 
compared (Fig. 2). Altogether these results show that ant is typical of VS and its presence in the S. 
pneumoniae mosaic strains indicates that a VS strain, probably a S. oralis or S. mitis, was the donor 
in the recombination event that originated the mosaic parE and parC genes. S. oralis and S. mitis 
are the most closely related species to S. pneumoniae on the basis of 16S rRNA sequence, which 
exhibits more than 99% identity with S. pneumoniae, although the DNA-DNA similarity values for 
their total chromosomal DNAs is less than 60% (30). Analysis of the genetic structure of the five S. 
pneumoniae mosaic strains (Fig. 4) suggests that the initial interchange that originated these mosaic 
strains included the whole parE-ant-parC chromosomal region. However, further reorganizations 
by recombination with VS or S. pneumoniae probably occurred, as deduced from the analysis of the 
gyrA, parC and parE genes of strain 4319 (Fig. 3) and of the gyrA and parC genes of strains 3180 
and 3870 (21).  
 We have not found identity between the ant sequences of VS and S. pneumoniae mosaic 
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strains. However, identity was observed between ant of S. pneumoniae strains 3870 and 4589 (Fig. 
2). Although these strains had identical ant sequence, they were isolated from unrelated patients in 
different years, had different pulse-field-gel electrophoresis patterns (data not shown) and different 
nucleotide sequences in their parC, parE, gyrA, and atpCA genes. However, both strains share the 
same physical structure in their parE-ant-parC region and ant sequences, suggesting that they have 
interchange the parE-ant-parC region with a closely-related VS strain.  
 We have observed a low prevalence (11%, 5 out of 46) of S. pneumoniae strains with mosaic 
structure in the parE-parC region among the CipR isolates. These strains were of serotype 23F (2 
out of 5 strains) or not-typeable (3 out of 5 strains) and all of them were also resistant to penicillin 
and other drugs. Since the 23F serotype is one of the most common among penicillin-resistant 
isolates in Spain and worldwide (17, 34, 37), it would be possible for these mosaic strains to be 
spread in a near future.  
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FlGURE LEGENDS 
Figure 1. Nucleotide sequence variations in the ParC, ParE, and GyrA QRDRs. The nucleotides 
present at each polymorphic site are shown for strain R6, but only sites that differ are shown for 
the other strains. Changes yielding amino acid substitutions, including those involved in 
fluoroquinolone resistance, are showed in boldface. Codon numbers are indicated in vertical 
format above the sequences. Positions 1, 2, and 3 in the fourth row refer to the first, second, and 
third nucleotides in the codon. Strains whose sequences do not differ from that of R6 more than 
1% are shadowed in gray. 
Figure 3. Mosaic structure of the gyrA, parC and parE genes of the S. pneumoniae and VS 
strains indicated. The locations of the QRDRs are represented at the top of the gyrA and parC 
sequences. The position of the active Tyr residues (Y-120 in GyrA and Y- 118 in ParC) that bind 
DNA, and the Ser residues that are changed in strain 4391 (S-81 in GyrA and S-79 in ParC), and 
are involved in resistance, are marked. Blocks showing the percentage sequence divergence from 
the corresponding regions of S. pneumoniae R6 strain are indicated. White box, region of 
sequence that differ by  1.5%; gray boxes, regions that differ by more than 1.5% but less than 
9%; black boxes, regions that differ by  9%. Strains used were S. pneumoniae (SPN) R6 
(GenBank accession number AE008451); SPN TIGR4 (accession number AE007391); SPN 
4391; S. mitis (SMI) NCTC 12261; and S. oralis (SOR) NCTC 11427. 
Figure 2. UPGMA trees of concatenated atpC and atpA, full-length parE genes , and ant genes. 
Phylogenetic and molecular evolutionary analyses were conducted using MEGA version 2.1 by 
using the UPGMA method. Only bootstrap confidence intervals exceeding 90% are shown. The 
accession numbers of each nucleotide sequence is shown in parentheses.  
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Figure 4 . Restriction map of the parE-parC region of S. pneumoniae and VS strains and its 
genetic organization as deduced from Southern blot experiments and nucleotide sequence 
analyses.  E, EcoRV; N, NcoI.  The parE and parC genes with a mosaic structure are showed 
with stripped arrows. 
Figure 5 . Southern blot hybridization of S. pneumoniae and VS strains with an ant probe. 
Chromosomal DNAs from the strains indicated was cleaved with EcoRV + NcoI and the 
fragments separated in 0.8% agarose gels. The gels were blotted and the blot was probed with a 




TABLE 1. Oligonucleotides used in this work 
 
Name Sequence (5’-3’)a Nucleotide positonsb 
antDOWN  TCATGAGTCTTCTCCTCTCGC Complementary to 853 to 873 of ant 
antUP  GCTGTCGCCATGTCTGGTTCACG 76 to 98 of ant 
atpB56  GACGGGCTTCTTCAGCTCTGTC Complementary  to 169 to 147 of atpB 
atpWO gcgcatgcTTAAAGGAGAATTTGTTATGAA –15 to 5 of atpC 
gyrADOWN gcgctctagAGTAATATCAGAAATCCTGCTAGG Complementary  to 2524 to 2501of gyrA 
gyrAUP1  gcgctctagaTGGTTTAGAGGCTGAAATAGAC 77 to 56 of gyrA 
parCDOWN  CGTTACTGTCATATTCCACTCC Complementary to 124 to 145 of parC 
parCUP   GAACACGCCCTAGATACTGTG 103 to 83  of parC 
parC26R GAATATCTGGCAAAGCCCGGTCTTG Complementary to 76 to 100 of parC 
parEDOWN  gcgcaagcTTAAAACACTGTCGCTTCTTCTAGCG Complementary to 1919 to 1944 of parE  
parEDOWNR CGCTAGAAGAAGCGACAGTG 1919 to 1938 of parE  
parEUP  cgcgcataTGTCAAAAAAGGAAATCAATATTAAC 2 to 27 of parE 
a The 5’ end of some of the primers contained a sequence including an NdeI (parEUP), HindIII (parEDOWN), SphI (atpWO) or XbaI 
(gyrAUP1 and gyrADOWN) restriction sites, which are shown underlined.  
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b Nucleotide and amino acid numbering refers to the genes and proteins obtained from the S. pneumoniae R6 sequence, with the first 
nucleotide or amino acid at position 1. 
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TABLE 2. Phenotypes of fluoroquinolone-resistant S. pneumoniae and S. mitis strains and amino acid changes in their DNA 
topoisomerase genes  
 





Amino acid change in the QRDR of:c   
      ParC  GyrA  ParE 
SPN ATCC 49619  19F S      1 None  None  None  
SPN R6   S      0.5 None  None  None  
SPN 3180 1994 NT S  128 S79F, N91D S81Y, S114G None 
SPN 3870 1996 NT S    64 S79F, N91D S81Y, S114G None 
SPN 4391  1997 23F S  128 S79Y, N91D S81F, S114G  None 
SPN 4589 1998 NT S    64 S79F, N91D S81F, S114G None 
SPN 4638 1998 23F S    32 S79Y, K137N S81F I460V 
SPN 5237 1999 23F S      8 S79N, N91D, I126V,E135D S81Y None 
SOR ATCC 10557   R      2 N91D S114G  None 
SOR NCTC 11427   R      2 N91D S114G None 
SMI NCTC 12261   R      1 N91D S114G  None 
SMI 75414-2 2000  R   32 D83Y, N91D S81F, S114G None 
SMI 181731-3 1999  R     64 S79F, N91D S81F, M90G, S114G None 




a NT, not typeable 
b CIP, ciprofloxacin  
c Residues involved in ciprofloxacin resistance are showed in boldface, and when double-underlined, that are located in a gene with a 
mosaic structure. No changes in GyrB were found. 
 
 
